secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2026-05-11T23:59:59+00:00
Accession:  0001193125-26-215720
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Q1 net loss $120.9M; BLA for z-rostudirsen on track for Q2 2026
--------------------------------------------------------------------

- Net loss of $120.9M ($0.73 per share) vs $115.4M ($1.05) in Q1 2025.
- Cash and marketable securities $972.2M; expected to fund operations into Q1 2028.
- R&D expenses $100.9M (down from $106.4M); G&A $24.4M (up from $15.9M) due to launch prep.
- Positive pre-BLA meeting with FDA; BLA submission for z-rostudirsen in exon 51 DMD on track for Q2 2026.
- ACHIEVE trial enrollment target of 60 participants reached; Phase 3 HARMONIA trial for z-basivarsen in DM1 initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312526215720/0001193125-26-215720-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312526215720/dyn-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-215720

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer